Abstract
We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.
| Original language | English |
|---|---|
| Journal | Leukemia and Lymphoma |
| Volume | 57 |
| Issue number | 1 |
| Pages (from-to) | 125-8 |
| Number of pages | 4 |
| ISSN | 1042-8194 |
| DOIs | |
| Publication status | Published - 2016 |
Keywords
- Aged
- Aged, 80 and over
- Blood Platelets
- Denmark
- Disease Management
- Female
- Humans
- Janus Kinases
- Male
- Middle Aged
- Mutation
- Platelet Count
- Primary Myelofibrosis
- Protein Kinase Inhibitors
- Pyrazoles
- Severity of Illness Index
- Thrombocytopenia
- Treatment Outcome
- Case Reports
- Journal Article
Fingerprint
Dive into the research topics of 'Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS